

- 953 Imported Human Rabies France, 1992
 - 955 Publication of CDC Surveillance Summaries
 - 961 Notices to Readers

MORBIDITY AND MORTALITY WEEKLY REPORT

International Notes

Imported Human Rabies — France, 1992

Wildlife rabies has been enzootic in France since 1968; however, 13 of the 14 human cases in France were imported, and one was in a person infected through a corneal transplant (1). On May 9, 1992, a 3-year-old boy who resided in Algeria died from rabies encephalitis in Paris. This report summarizes the investigation of this case by the Pasteur Institute.

On March 17, 1992, the boy was chased by a dog in his village in Algeria, fell, and sustained a wound on his forehead. Witnesses confirmed that the boy's wound resulted when he fell on a stone and that he was not bitten or licked by the dog. No rabies treatment was started. The boy remained well until April 15, when he complained of headache. He was hospitalized in Algeria on April 19 with agitation, hyperthermia, aerophobia, and hydrophobia. On April 23, he was transferred from Algeria to an intensive-care unit at a hospital in Paris with suspicion of viral encephalitis of unknown origin. Tests for rabies antibody in serum and cerebrospinal fluid (CSF) on April 24 were negative, and other etiologies (e.g., diphtheria and organophosphate poisoning) were considered. On April 30 he became comatose and was placed under respiratory monitoring; he received external cardiac pacing after atrioventricular dissociation. Daily electroencephalographic monitoring showed decreasing brain activity. He developed diabetes insipidus on May 8 and died on May 9, 25 days after onset of symptoms and 17 days in the intensive-care unit.

A second serum sample obtained on May 5 was positive for rabies antibody by enzyme-linked immunosorbent assay and rapid fluorescent focus inhibition test. Testing using daily controls indicated rising antibody titers until death on May 9. Neck-skin biopsies and corneal smears performed on May 5 and May 9 were negative by fluorescent antibody test (FAT). CSF samples obtained on April 24 and April 27 and on May 5 and May 9 were negative for rabies antigen detection by rapid rabies enzyme immunodiagnosis (RREID) test and for rabies virus isolation on neuroblastoma cells; however, the CSF sample obtained on May 9 was positive for rabies antibody. Saliva samples were obtained daily from May 5 through May 9; the samples of May 7 and May 9 were positive by RREID on cell sediment. Complete autopsy was not authorized

Rabies — Continued

by the family, but a postmortem retro-orbital brain sample confirmed rabies diagnosis by FAT, isolation on neuroblastoma cells, RREID, and mouse inoculation test. Mouse inoculation tests with saliva and CSF remained negative.

Postexposure rabies prophylaxis was administered to 143 hospital staff and family members in Paris who had been exposed to the patient during nursing and hospital care before diagnosis and who had handled saliva and body samples. Family members and exposed hospital staff in Algeria were informed of the diagnosis. Exact data about the number of persons given rabies postexposure prophylaxis in Algeria are not available.

Investigations in the boy's hometown revealed that the dog that chased him in March did not remain healthy, as reported to the family, but died (or was killed) shortly after the incident and may have been implicated in another rabies fatality of a child at the end of April 1992.

Reported by: P Sureau, MD, M Herzog, MD, H Bourhy, DVM, Rabies Unit, Pasteur Institute; M Cloup, MD, P Hubert, MD, S Couderc, MD, Pediatric Intensive Care Unit, Sick Children's Hospital, Paris. Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

Editorial Note: Although rabies is enzootic among wildlife species, human rabies is rarely acquired in France. Human and animal rabies have been reported in countries of northern Africa in which most cases imported into France were acquired. In every case, the vector animal was a dog. Worldwide, dogs are responsible for more than 90% of human cases (2). In the case described in this report, no dog bite was documented; consequently, because a definite exposure was not established, post-exposure prophylaxis was not given to the boy. However, the putative short incubation period (29 days) is consistent with an exposure to the upper body (3). Because many patients with rabies have died or are severely ill at the time rabies is diagnosed, it is sometimes not possible to determine an exposure. The possible contact with the dog was the probable exposure, but the boy might have received other unreported bites or exposure to rabies virus.

The early manifestations of rabies are usually nonspecific and can be difficult to differentiate from other encephalitic diseases. Rabies progresses to one of two distinct presentations: the most common furious form, characterized by hydrophobia, aerophobia, or episodic agitation and anxiety; or the least common paralytic form. Rabies should be considered in any patient with rapidly progressive encephalitis of unknown etiology, particularly in patients who have lived in an area with enzootic canine rabies (4).

Rabies postexposure prophylaxis is recommended for all persons bitten or scratched by animals that may be rabid. Rabies rarely results from exposures other than bites, scratches, contact with mucous membranes, or contact with an open wound with saliva or other potentially infectious rabies material from a person or animal with rabies. When a bite or mucous-membrane exposure cannot be excluded, postexposure treatment should be given to persons who have had physical contact with rabid animals. Treatment should be initiated as soon as possible after bites or scratches by known or suspected rabid animals.

Postexposure prophylaxis is recommended for persons who report a possible infectious exposure (e.g., bite, scratch, open wound, or mucous-membrane contamination with saliva or other infectious material) to a human with rabies. However,

Rabies — Continued

exposure to a human with rabies has not been implicated as a means of rabies transmission except following cornea transplantation from donors who died from rabies. Casual contact with a person with rabies (i.e., touching the patient) or contact with noninfectious fluid or tissue (e.g., blood, urine, or feces) does not constitute an exposure and is not an indication for prophylaxis (5). In this report, the number of hospital employees and family members (143) given postexposure prophylaxis was unusually high; however, the delay in definite diagnosis was considered to have resulted in increased exposure to the child.

References

- 1. CDC. Human-to-human transmission of rabies via a corneal transplant—France. MMWR 1980;29:25–6.
- 2. World Health Organization. World survey of rabies XXV (for year 1989). Geneva: World Health Organization, Division of Communicable Diseases, Veterinary Public Health Unit, 1992; publication no. WHO/Rabies/92.203.
- 3. Fekadu M. Rabies in Ethiopia. Am J Epidemiol 1982;115:266-73.
- CDC. Health information for international travel, 1991. Atlanta: US Department of Health and Human Services, Public Health Service, 1991:113–6; DHHS publication no. (CDC)91-8280.
- 5. Anderson LJ, Winkler WG, Vernon AA, Helmick CG, Roberts MR. Prophylaxis for persons in contact with patients who have rabies. N Engl J Med 1980;320:967–8.

Surveillance Summaries

Publication of CDC Surveillance Summaries

Since 1983, CDC has published the *CDC Surveillance Summaries* under separate cover as part of the *MMWR* series. Each report published in the *CDC Surveillance Summaries* focuses on public health surveillance; surveillance findings are reported for a broad range of risk factors and health conditions.

Summaries for each of the reports published in the most recent (September 4, 1992) issue of the *CDC Surveillance Summaries* (1) are provided below. All subscribers to *MMWR* receive the *CDC Surveillance Summaries*, as well as the *MMWR Recommendations and Reports*, as part of their subscriptions.

ABORTION SURVEILLANCE—UNITED STATES, 1989

Since 1980, the number of legal induced abortions reported to CDC has remained stable, varying each year by <5%. In 1989, 1,396,658 abortions were reported—a 1.9% increase from 1988. The abortion ratio for 1989 was 346 legal induced abortions/1000 live births, and the abortion rate was 24/1000 women ages 15–44 years. The abortion ratio was highest for black women and women of other minority racial groups and for women <15 years of age. Women undergoing abortions tended to be young, white, and unmarried; to have had no previous live births; and to be having the procedure for the first time. Approximately half of all abortions were performed before the 8th week of gestation, and 87% were before the 13th week of gestation. Younger women tended to obtain abortions later in pregnancy than older women.

This report also includes newly reported abortion-related deaths for 1986 and 1987, as well as an update on abortion-related deaths for the period 1978–1985. Ten deaths in 1986 and six deaths in 1987 were associated with legal induced abortion. The case-




FIGURE I. Notifiable disease reports, comparison of 4-week totals ending December 19, 1992, with historical data — United States

*The large apparent decrease in reported cases of measles (total) reflected dramatic fluctuations in the historical baseline.

[†]Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

TABLE I. Summary — cases of specified notifiable diseases, United States, cumulative, week ending December 19, 1992 (51st Week)

	Cum. 1992		Cum. 1992
AIDS* Anthrax Botulism: Foodborne Infant Other Brucellosis Cholera Congenital rubella syndrome Diphtheria Encephalitis, post-infectious Gonorrhea Haemophilus influenzae (invasive disease)	42,978 1 19 59 3 84 97 9 4 108 471,488 1,222	Measles: imported indigenous Plague Poliomyelitis, Paralytic [†] Psittacosis Rabies, human Syphilis, primary & secondary Syphilis, congenital, age < 1 year ^{\$} Tetanus Toxic shock syndrome Trichinosis Tuberculosis	130 2,068 12 32,637 1,639 39 218 39 22,592
Hansen Disease Leptospirosis Lyme Disease	148 46 7,777	Tularemia Typhoid fever Typhus fever, tickborne (RMSF)	153 376 489

"Updated monthly; last update December 5, 1992.

Four cases of suspected pollomyelitis have been reported in 1992; 6 of the 9 suspected cases with onset in 1991 were confirmed, and 5 of the 8 suspected cases with onset in 1990 were confirmed; all were vaccine associated. ⁵Reports through second quarter 1992.

ł

MMWR

December 19, 1992, and December 21, 1991 (51st Week)												
		Aseptic	Encept		_		He	patitis (\	/iral), by		Legionel-	Luma a
Reporting Area	AIDS*	Menin- gitis	Primary	Post-in- fectious		rrhea	A	В	NA,NB	Unspeci- fied	losis	Lyme Disease
	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1991	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992
UNITED STATES	42,978	11,303	662	108	471,488	590,681	20,603	14,530	5,596	697	1,240	7,777
NEW ENGLAND	1,607	437	28	-	9,987	13,875	579	512	100	25	49	1,593
Main e N.H.	44 45	42 43	3 3	-	85 124	154 183	30 31	27 41	6 20	2	2 8	5 41
Vt.	26	26	6	-	26	53	14	13	16	-	2	8
Mass. R.I.	796 93	167 159	13 3	-	3,566 619	5,942 1,190	287 148	401 17	52 6	23	25 12	228 276
Conn.	603	-	-	-	5,567	6,353	69	13	-	-	12	1,035
MID. ATLANTIC	11,036	898	25	8	53,266	69,263	1,531	1,855	317	23	313	4,653
Upstate N.Y. N.Y. City	1,467 6.393	451 160	6	2	10,722 17,991	12,476 27,091	337 682	472 362	183 5	13	102 8	2,885 24
N.J.	1,976	-	-	-	7,298	11,166	263	480	95	-	43	681
Pa.	1,200	287	19	6	17,255	18,530	249	541	34	10	160	1,063
E.N. CENTRAL Ohio	3,853 686	1,897 486	165 54	29 2	89,483 27,041	113,186 34,685	2,737 433	1,713 228	758 93	25 4	331 152	137 62
Ind.	380	225	13	12	8,863	11,145	750	201	25	2	33	21
111. NAV-1-	1,866	548	70	6	29,944	34,268	636	311	99	8	31	27
Mich. Wis.	683 238	577 61	25 3	9	19,823 3,812	25,984 7,104	147 771	562 411	464 77	11	72 43	27
W.N. CENTRAL	1,196	623	43	6	25,463	29,019	2,803	666	285	35	79	342
Minn. Iowa	213 78	104	20	-	2,889	3,083	756	81	20	3	6	175
No.	654	105 252	8	3	1,462 16,166	1,974 17,254	53 1,284	33 443	7 221	5 25	18 29	32 101
N. Dak.	5	2	3	-	59	89	115	3	4	Ĩ	2	1
S. Dak. Nebr.	8 55	10 38	3 4	1 2	163 8	346 1,817	213 253	5 42	- 18		1	1
Kans.	183	112	4 5	-	4,716	4,456	129	42 59	18	1	18 5	15 17
S. ATLANTIC	9,729	1,738	167	51	138,375	174,307	1,325	2,467	915	122	199	645
Del. Md.	122	53	7		1,736	2,830	56	205	189	2	23	211
D.C.	1,207 685	212 28	16 1		16,080 6,551	19,656 8,905	242 15	373 83	33 278	10	37 20	175 3
Va.	623	285	37	13	14,654	17,828	147	185	42	47	20	113
W. Va. N.C.	49 634	38 203	75 26	:	807 24,321	1,259 33,394	10 106	48 401	6 83	28	40	13 73
S.C.	260	205	- 20		10,421	14,055	22	53	1	1	16	2
Ga. Fla.	1,207	214	2	-	36,586	41,625	201	301	131	-	16	23
E.S. CENTRAL	4,942 1,309	679 548	3 34	38	27,219	34,755	526	818	152	34	27 60	32 68
Ky.	202	200	34 21	-	48,424 4,672	58,963 5,825	343 128	1,320 104	1,311 6	2	26	26
Tenn.	419	138	7	-	15,404	20,017	124	1,079	1,287	-	28	33
Ala. Miss.	454 234	134 76	5 1		16,914 11,434	19,425 13,696	51 40	133	17	1	6	9
W.S. CENTRAL	4,053	1,188	67	5	52,320	66.575	2.056	1.852	180	169	26	117
Ark. La.	269	20	7		7,202	7,888	134	96	8	6	1	17
Okla.	672 219	77	10 3	1 2	14,219 5,468	15,133 6,764	213 204	196 189	92 49	3 5	6 12	6 25
Tex.	2,893	1,091	47	2	25,431	36,790	1,505	1,371	31	155	7	69
MOUNTAIN Mont.	1,236	387	30	5	11,826	12,527	2,970	742	271	63	97	16
Idaho	20 34	12 24	1	1	110 113	100 159	85 97	36 81	28	1 3	9 4	2
Wyo.	5	6	2		59	93	12	17	56	-	1	5
Colo. N. Mex.	382 110	123	11	1	4,170	3,809	836	110	92	27	19	-
Ariz.	348	53 100	4 6	1	909 4,102	973 4,539	287 1,069	207 164	31 28	8 15	3 32	2
Utah Nev.	118	19	3	i	350	332	483	25	29	8	6	6
PACIFIC	219	50	3	-	2,013	2,522	101	102	7	1	23	1
Wash.	8,959 506	3,587	103	4	42,344	52,966	6,259	3,403	1,459	233	86 13	206 13
Oreg.	274	-	2		3,811 1,619	4,668 1,990	782 485	347 278	160 78	8 9	13	- 13
Calif. Alaska	8,023	3,473	94	3	35,749	44,746	4,713	2,742	1,011	205	69	191
Hawaii	14 142	18 96	7	1	676 489	867 695	118 161	18 18	6 204	2 9	3	2
Guam	-	6	-	-	469	31	5	2		6	-	1
P.R. V.I.	1,546	163	2	-	233	523	43	402	164	17	1	-
Amer. Samoa	10	-	-	-	107 50	342	5	7	-	-	-	-
C.N.M.I.	-	-	-	-	50 75	63 100	1 3	1	-	-	-	-
N: Not notifiable		1.1.1										

TABLE II. Cases of selected notifiable diseases, United States, weeks ending December 19, 1992, and December 21, 1991 (51st Week)

N: Not notifiable U: Unavailable *Updated monthly; last update December 5, 1992.

C.N.M.I.: Commonwealth of Northern Mariana Islands

			Measle	s (Rube	ola)		Menin-								
	Malaria	India	enous		orted*	Total	gococcal Infections	Mu	mps	1	Pertussi	5		Rubell	8
Reporting Area	Cum. 1992	1992	Cum. 1992	1992	Cum. 1992	Cum. 1991	Cum. 1992	1 9 92	Cum. 1992	1992	Cum. 1992	Cum. 1991	1992	Cum. 1992	Cum. 1991
UNITED STATES	980	1	2,068	2	130	9,468	2,080	32	2,390	67	3,098	2,605	-	146	1374
NEW ENGLAND	46	-	54	-	13	87	116	-	20	23	307 11	283 54	-	6 1	4
Maine N.H.	1	2	- 16	-	4	7	10 6	-	6	18	125	22	-	-	1
Vt.	1	-	16	:	- 5	5 40	9 51	-	1	5	18 103	5 176	:	-	2
Mass. R.I.	24 5	-	20	-	-	4	2	-	2	-	6	26	-	4	1
Conn.	12	-	2	-	4	31 4,902	38 251	- 9	8 183	6	44 291	286		9	580
MID. ATLANTIC Upstate N.Y.	274 44	:	208 103	-	21 10	401	108	9	83	6	120	156	-	3	539 6
N.Y. City N.J.	151 50	:	42 58	-	8 2	2,000 1,035	25 46	-	10 17	-	20 48	39 20	-	3	2
Pa.	29	-	5	-	ī	1,466	72	-	73	-	103	71		3	33 321
E.N. CENTRAL	64 14	-	40	-	14 6	97 11	344 81	5 1	327 117	10 2	554 122	413 104	2	11	283
Ohio Ind.	12	-	20	-	-	6	59	-	11	8	61 44	76 74	-	- 9	3 9
III. Mich.	20 14	-	9 11	-	4	28 43	90 87	4	103 81	-	15	37	-	2	25
Wis.	4	-	-	-	2	9	27	-	15	-	312	122	-	- 8	1 19
W.N. CENTRAL	43 17	-	8 7	-	8 5	59 27	100 20	1	83 24	7 1	313 108	224 87	:	-	6
Minn. Iowa	4	-	-	-	3	17	16	-	13	2	11 114	26 81	-	3 1	6 5
Mo. N. Dak.	12 1	-	-	:	:	1	35 1	1	35 3	-	14	4	-	-	ĩ
S. Dak.	2	-	-	-	-	1	1 10	-	- 6	3 1	17 17	5 9	:	:	-
Nebr. Kans.	1 6	-	1		-	13	17	-	2	-	32	12	-	4	1
S. ATLANTIC	210	-	123	-	15	631	372	4	810 8	5	194 7	247	-	22	10
Del. Md.	5 62	-	1 10	:	7	21 177	2 36	4	84	3	39	55	-	6	1
D.C.	14 48	-	11	•	1 5	30	3 58	-	7 58	-	1 16	2 24	:	1	1
Va. W.Va.	2	-	-	-	-	-	17	-	27	-	9 44	9 39	-	1	2
N.C. S.C.	13 1	-	23 29		1	44 13	81 22	-	217 51	-	10	15	-	7	-
Ga.	16 49	-	2 46	:	1	15 331	58 95	-	75 283	2	17 51	50 53	:	;	6
Fla. E.S. CENTRAL	19	1	450		18	29	135	-	60	2	33	94	-	1	100
Ky.	1	1	449	:	2	23 4	44 39	:	- 15	1	1 10	- 38	:	1	100
Tenn. Ala.	11 6	-	-	-	-	2	40	-	14	1	19	50	-	•	-
Miss.	1	-	1	-	16	-	12	2	31 411	2	3 171	6 169	•		10
W.S. CENTRAL Ark.	31 3	-	1,059	:	5	218 5	169 19	-	9	-	19	15	-	•	1
La.	1	•	12	:	:	-	31 20	:	24 21	2	15 49	17 49	-	:	1 2
Okla. Tex.	22		1,047	-	5	213	99	2	357	-	88	88	-	-	6
MOUNTAIN	34	-	25	2	9	1,266	96 15	1	153 2	5	415 9	345 6	:	9	38 11
Mont. Idaho	1	-	-	-	-	452	10		4	3	43	29 3	•	1	-
Wyo. Colo.	10	-	1 21	21	8	3 13	3 23	1	1 31	2	93	140		2	3
N. Mex.	5	-	1	-	1	98 457	10 19	N	N 78	-	103 124	47 77	-	2	4
Ariz. Utah	10 5	-	-		-	224	4	-	24	-	41	41	-	22	11
Nev.	3	-	-	-	- 27	19 2.179	12 497	- 10	13 343	-7	2 820	2 544	:	2 80	7 292
PACIFIC Wash.	259 17	-	101	-	11	66	76	2	17	2	222	137	-	8	8
Oreg. Calif.	17 213	-	3 56	:	1	91 1,985	71 333	N 8	N 297	1 4	45 486	65 257	-	2 47	5 267
Alaska	1	-	8	-	1	5	10	-	3 26	-	14 53	13 72	-	23	1
Hawaii	11 2	- U	34 10	ט	11	32	7	U	20 12	U			- U	23	
Guam P.R.	-	13	481	-	-	94	3	1	2	-	11	61	-	-	1
V.I. Amer. Samoa	-	Ū	-	Ū	-	2 24	-	Ū	21	Ū	6	-	Ū	-	:
C.N.M.I.	-	U	1	U	1	•		U	-	U	2	-	<u> </u>		

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending December 19, 1992, and December 21, 1991 (51st Week)

*For measles only, imported cases include both out-of-state and international importations. N: Not notifiable U: Unavailable [†] International [§] Out-of-state

958

	Deven		992, and D	coenin	GI 2 I,	1331 (3	100 1100	, x ,	
Reporting Area	Syphilis (Primary & Secondary)		Toxic- Shock Syndrome	Tuber	culosis	Tula- remia	Typhoid Fever	Typhus Fever (Tick-borne) (RMSF)	Rabies, Animal
	Cum. 1992	Cum. 1991	Cum. 1992	Cum. 1992	Cum. 1991	Cum. 1992	Cum. 1992	Cum. 1992	Cum. 1992
UNITED STATES	32,637	40,690	218	22,592	23,000	153	376	489	7,675
NEW ENGLAND	683	1,011	15	524	653	1	30	8	889
Maine N.H.	5 74	3 12	2 6	19 18	33 5	-	- 1	1	- 9
Vt.	1	2	-	6	10	-	-	-	23
Mass. R.I.	323 38	486 54	5 2	297 46	373 75	1	20	3 2	50
Conn.	242	454	-	138	157	-	9	2	807
MID. ATLANTIC Upstate N.Y.	4,541 328	6,789 632	25 10	5,192 599	5,446 426	1	99 18	49 17	2,403 1,326
N.Y. City	2,449	3,482	-	3,067	3,454	-	42	6	18
N.J. Pa.	542 1,222	1,154 1,521	15	892 634	884 682	1	25 14	14 12	704 355
E.N. CENTRAL	4,925	4,961	53	2,248	2,266	1	42	29	154
Ohio	822	649	17	330	365	-	10 1	17 4	14 19
Ind. III.	265 2,266	190 2,345	5 10	204 1,164	242 1,162	1	26	2	39
Mich. Wis.	901 671	1,136 641	21	462 88	395 102	:	4 1	3 3	15 67
W.N. CENTRAL	1,636	886	39	514	497	53	7	34	1.016
Minn.	89	68	7	141	95	-	2	-	165
lowa Mo.	53 1,291	68 566	7 9	43 216	60 220	37	1 3	3 23	171 32
N. Dak. S. Dak.	1	1	4	7	10	•	-	- 1	145 124
S. Dak. Nebr.	1	1 17	4	27 25	31 20	11 2	1	2	13
Kans.	201	165	8	55	61	3	-	5	366
S. ATLANTIC Del.	8,663 197	11,846 183	24 3	4,221 52	4,318 34	5	36 1	173 14	1,771 209
Md.	592	972	2	395	452	1	7	17	529
D.C. Va.	399 706	698 867	- 3	116 347	180 310	2	1 5	24	17 356
W. Va.	19	31	2	91	65	-	1	5 64	50 45
N.C. S.C.	2,341 1,165	1,972 1,527	3 1	579 377	570 416	1	2	8	161
Ga. Fla.	1,681 1,563	2,898	5	861	834	1	2 17	37 3	361 43
E.S. CENTRAL	4,130	2,698 4,496	5 3	1,403 1,473	1,457 1,546	10	5	64	190
Ky.	177	110	-	387	336	2	1	7	61
Tenn. Ala.	1,183 1,365	1,437 1,686	3	431 409	524 398	8	1	54 3	41 87
Miss.	1,405	1,263	-	246	288	-	3	-	1
W.S. CENTRAL	6,041	7,577	5	2,717	2,662	46	17	115 25	681 44
Ark. La.	827 2,529	736 2,746	1	228 217	245 238	31 2	1	1	8
Okla. Tex.	452 2,233	204 3,891	3 1	154 2,118	165 2,014	13	15	88 1	286 343
MOUNTAIN	321	552	20	553	608	29	6	11	240
Mont.	7	6	1	13	10	13	-	3	24 7
ldaho Wyo.	1 8	4 10	2 1	24	15 5	- 1	1	1 4	82
Colo.	59	87	6	52	83	5	2 1	1	26 9
N. Mex. Ariz.	40 158	30 344	1 4	80 251	74 304	5	i	-	69
Utah Nev.	7 41	9 62	5	61 72	54 63	2 3	1	1	6 17
PACIFIC	1,697	2,572	34	5,150	5.004	7	134	6	331
Wash.	74	187	3	301	302	2	9	3	2
Oreg. Calif.	49 1,560	84 2,289	2 29	125 4,405	123 4,312	2	2 116	3	314
Alaska Hawaii	5 9	4	-	52 267	66 201	3	7	-	15
Guam	3	8		267	201	-	3	-	-
P.R.	338	424	-	225	211	-	1	-	44
V.I. Amer. Samoa	69	95	-	3	3	-	1	-	-
C.N.M.I.	6	9	-	53	26	-	i	-	-

TABLE II. (Cont'd.) Cases of selected notifiable diseases, United States, weeks ending December 19, 1992, and December 21, 1991 (51st Week)

U: Unavailable

			13, 1	5, 1552 (515t Week)											
	A	II Cau	ses, By	Age ()	'ears)		P&I [†]		1	All Cau	ises, By	Age (Y	ears)		P&i [†]
Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND	645	456		55	16	12	69	S. ATLANTIC	1,120	677	226	147	33	37	60 U
Boston, Mass. Bridgeport, Conn.	189 40	126 25	38 9	14 3	7	4	27 3	Atlanta, Ga. Baltimore, Md.	170	U 95	U 32	U 32	Ŭ 7	Ŭ 4	8
Cambridge, Mass.	17	15	1	1	-	-	2	Charlotte, N.C.	76	49	19	3	4	1	4 9
Fall River, Mass. Hartford, Conn.	27 56	24 35		2 7	3	-	1 4	Jacksonville, Fla. Miami, Fla.	119 143	80 72	19 34	11 26	1 8	8 3	9 3
Lowell, Mass.	24	35		1	1	2	6	Norfolk, Va.	59	35	15	20	ĩ	5	3
Lynn, Mass.	14	10	2	1	1	-	-	Richmond, Va.	86	51	17	14	، 2	22	8
New Bedford, Mass New Haven, Conn.	s. 38 34	29 19	6 8	3 3	-	4	23	Savannah, Ga. St. Petersburg, Fla.	41 48	24 34	10 5	5 5	2	2	22
Providence, R.I.	45	35	5	5	-		8	Tampa, Fla.	182	127	31	12	5	27	16
Somerville, Mass.	6 42	5 27	1	- 9	-	:	1 3	Washington, D.C. Wilmington, Del.	170 26	88 22	42 2	34 2	3	3	5
Springfield, Mass. Waterbury, Conn.	33	27	3	2	1	-	-	-							-
Worcester, Mass.	80	63	11	4	-	2	9	E.S. CENTRAL Birmingham, Ala.	882 183	595 111	184 38	57 14	24 8	22 12	58 7
MID. ATLANTIC	2,821	1,853		303	64	81	116	Chattanooga, Tenn.	86	66	16	4	-	-	12
Albany, N.Y.	49 19	36	6 1	1	3	3	4	Knoxville, Tenn.	90 62	65 40	13 17	6 3	2 1	4	7
Allentown, Pa. Buffalo, N.Y.	100	17 68		1 5	4	3	3	Lexington, Ky. Memphis, Tenn.	198	131	44	13	8	2	14
Camden, N.J.	47	24	13	6	1	3	-	Mobile, Ala.	50	29	15	4	-	Ž	÷
Elizabeth, N.J. Erie, Pa.§	15 47	12 31		3	1	2	5	Montgomery, Ala. Nashville, Tenn.	66 147	54 99	8 33	4 9	5	1	2 13
Jersey City, N.J.	68	39	12	11	2	4	1	W.S. CENTRAL	1,196	760	252	99	45	38	60
New York City, N.Y.	1,590	1,021		204	30 2	45 2	48 3	Austin, Tex.	78	/60	252	10	45	- 30	7
Newark, N.J. Paterson, N.J.	64 30	27 14		14 4	-	2	-	Baton Rouge, La.	20	11	5	2	1	1	1
Philadelphia, Pa.	306	187	64	37	12	5	17	Corpus Christi, Tex. Dallas, Tex.	. 46 220	28 124	11 54	5 26	2 8	8	1 5
Pittsburgh, Pa.§ Reading, Pa.	105 20	72 16		6	5	6 1	7	El Paso, Tex. Ft. Worth, Tex.	69	53	14	1	-	1	9
Rochester, N.Y.	149	121	20	4	2	ż	9	Ft. Worth, Tex.	105	71	23	5 U	.4	2 U	6 U
Schenectady, N.Y.	22	19		1	ī	2	2 3	Houston, Tex. Little Rock, Ark.	U 99	U 51	U 24	9	U 5	10	5
Scranton, Pa.§ Syracuse, N.Y.	32 107	29 81		2	i	1	6	New Orleans, La.	140	84	33	12	5	4	
Trenton, N.J.	30	19	5	4	-	2	5	San Antonio, Tex. Shreveport, La.	225 57	145 37	48 12	14 5	11	7	15 3
Utica, N.Y. Yonkers, N.Y.	21 U	20 U		Ū	Ū	ບັ	1 U	Tulsa, Okla.	137	105	13	1Ŏ	6	2 3	8
E.N. CENTRAL	2,431	1,487	466	261	139	78	130	MOUNTAIN Albuquerque, N.M.	920 102	605 65	194 23	74 12	23 2	24	77 2
Akron, Ohio Canton, Ohio	67 31	51 25		5	1	-	1	Colo. Springs, Colo		34	13	1	1	-	7
Chicago, III.	627	259	142	110	98	18	26	Denver, Colo.	94	60	19	9	2	4	10
Cincinnati, Ohio	153	110		.9	8	2	20	Las Vegas, Nev. Ogden, Utah	182 24	116 18	42	18 2	5	1	15 4
Cleveland, Ohio Columbus, Ohio	170 196	110 134		19 12	4	8 9	6 8	Phoenix, Ariz.	230	141	53	22	5	9	25
Davton, Ohio	137	93	27	8	3	6	10	Pueblo, Colo. Salt Lake City, Utah	28 96	21 63	5 16	1 6	1	ż	17
Detroit, Mich. Evansville, Ind.	235 52	144 44		28 3	9 1	11	10 1	Tucson, Ariz.	115	87	19	3	3	3	6
Fort Wayne, Ind.	53	31	11	3	:	8	ż	PACIFIC	2,030	1,373	317	228	64	46	139
Gary, Ind.	14 h. 56	6 43		3	-	1	4	Berkeley, Calif.	24	19	3	2	-	-	4
Grand Rapids, Micl Indianapolis, Ind.	176	110		25	3	ź	11	Fresno, Calif. Glendale, Calif.	100 19	68 14	15 3	12	22	3	8 4
Madison, Wis.	47	32	8	2	1	4	7	Honolulu, Hawaii	78	48	18	8	2	2	3
Milwaukee, Wis. Peoria, III.	134 42	94 30		12	3	-	9 2	Long Beach, Calif.	103	77	12	7	5	2	12
Rockford, III.	41	28	9	2	1	1	5	Los Angeles, Calif. Pasadena, Calif.	461 49	301 33	48 6	81 4	27 4	4 2	18 2
South Bend, Ind.	42 98	31 68		4	ī	3	17	Portland, Oreg.	127	99	17	8	1	2	5
Toledo, Ohio Youngstown, Ohio	60	44		5	i	2	-	Sacramento, Čalif. San Diego, Calif.	180 155	112 104	37 22	17 21	3 1	10 7	20 11
W.N. CENTRAL Des Moines, Iowa	803 65	618 50		43 1	14 3	9 1	38 5	San Francisco, Calif San Jose, Calif.	210	107 145	36 47	27 10	1	24	1 23
Duluth, Minn.	25	23	1	1	-	-	-	Santa Cruz, Calif. Seattle, Wash.	26	24	2	-	-	-	4
Kansas City, Kans. Kansas City, Mo.	28 110	21 89	6 12	17	2	2	- 9	Spokane, Wash.	151 60	98 46	27 6	19 5	4	3 1	11
Lincoln, Nebr.	34	27	4	-	2	1	4	Tacoma, Wash.	114	78	18	7	6	4	9
Minneapolis, Minn.	195 87	144 64	34 14	14 5	2	3 2	10	TOTAL	12,848	8,424	2,383	1,267	422	347	747
Omaha, Nebr. St. Louis, Mo.	135	104	18	10	2	1	4								
St. Paul, Minn.	62	54 42	7 13	4	3	1	5								
Wichita, Kans.	62	42	13	4	3	-	1								

TABLE III. Deaths in 121 U.S. cities,* week ending December 19, 1992 (51st Week)

*Mortality data in this table are voluntarily reported from 121 cities in the United States, most of which have populations of 100,000 or more. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not

Totel includes unknown ages.

U: Unavailable.

960

Surveillance Summaries — Continued

fatality rate in 1986 was 0.8 abortion-related deaths/100,000 legal induced abortions and 0.4/100,000 in 1987.

Authors: Lisa M. Koonin, MN, MPH, Jack C. Smith, MS, Merrell Ramick, Herschel Lawson, MD, Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, CDC.

INFLUENZA SURVEILLANCE—UNITED STATES, 1991–92

During the 1991–92 influenza season, substantial levels of influenza activity began to be reported in the United States in early November 1991, 5–10 weeks earlier than in any of the previous nine influenza seasons. Influenza activity peaked from mid-December 1991 to mid-January 1992. By early March 1992, influenza activity as measured by all four surveillance systems had returned to baseline levels, 5–8 weeks earlier than average for the previous nine influenza seasons. The pneumonia and influenza deaths from the 121 cities participating in surveillance exceeded the epidemic threshold for 7 consecutive weeks during the season, demonstrating excess mortality due to influenza during this season.

Nationally, >99% of isolates were influenza A. Of these, 81% were influenza A(H3N2) and 19% were influenza A(H1N1). The majority of isolates characterized were antigenically similar to components in the 1991–92 influenza vaccine. However, an influenza A(H1N1) strain that had undergone antigenic drift was detected in many regions of the country, and this strain will be included in the 1992–93 influenza vaccine.

Authors: Joseph H. Kent, MD, Louisa E. Chapman, MD, MSPH, Leone M. Schmeltz, Lawrence B. Schonberger, MD, MPH, Epidemiology Activity, Office of the Director; Helen L. Regnery, PhD, Nancy J. Cox, PhD, The WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza, Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

Reference

1. CDC. CDC surveillance summaries (September 5). MMWR 1992;41(no. SS-5).

Notices to Readers

1993 Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults

On December 18, 1992, CDC published a revised classification system for human immunodeficiency virus (HIV) infection and an expanded surveillance case definition for acquired immunodeficiency syndrome (AIDS) among adolescents and adults in the United States (1).* Based on the clinical standard for immunologic monitoring of persons infected with HIV, the revised HIV classification system includes the CD4+ T-lymphocyte measurement in the categorization of HIV-related clinical conditions and replaces the HIV classification system published in 1986 (2). In addition, the expanded AIDS surveillance case definition includes all HIV-infected persons who have less than 200 CD4+ T-lymphocytes/µL or a CD4+ T-lymphocyte percent of total lymphocytes less

^{*}Single copies of the document will be available in mid-January from the CDC National AIDS Clearinghouse, P.O. Box 6003, Rockville, MD 20849-6003; telephone (800) 458-5231.

Notices to Readers -- Continued

than 14, or who have been diagnosed with pulmonary tuberculosis, invasive cervical cancer, or recurrent pneumonia. The new AIDS surveillance case definition retains the reporting criteria listed in the 1987 AIDS surveillance case definition (3). The objectives of the expansion are to reflect more accurately the number of persons with severe HIV-related morbidity and immunosuppression and to simplify the reporting process. Beginning January 1, 1993, this expanded AIDS surveillance case definition is to be used by all states and territories for AIDS case reporting.

References

- 1. CDC. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41(no. RR-17).
- 2. CDC. Classification system for human T-lymphotropic virus type III/Iymphadenopathyassociated virus infections. MMWR 1986;35:334-9.
- 3. CDC. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36(no. S-1).

Release of the 1992 Supplement to the Work-Related Lung Disease Surveillance Report

CDC's National Institute for Occupational Safety and Health (NIOSH) has released the Work Related Lung Disease (WoRLD) Surveillance Report, Supplement 1992 (1). The original report, released in 1991, summarizes surveillance data for occupational respiratory diseases. The 1992 supplement is an update and includes data not previously presented from multiple cause-of-death data, the National Hospital Discharge Survey, and the Sentinel Event Notification System for Occupational Risks (SENSOR) program. The report, compiled by the Division of Respiratory Disease Studies, contains information of use to public health officials, researchers, management and labor officials, and others working in occupational health disciplines.

Copies of the original WoRLD report and the 1992 WoRLD supplement are available from the NIOSH hotline, (800) 356-4674 ([800] 35-NIOSH).

Reported by: Div of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC.

Reference

1. NIOSH. Work related lung disease surveillance report, supplement 1992. Morgantown, West Virginia: US Department of Health and Human Services, Public Health Service, CDC, 1992; DHHS publication no. (NIOSH)91-113S.

Approval of Japanese Encephalitis Vaccine

The Food and Drug Administration has approved an inactivated Japanese encephalitis vaccine (JVax*) distributed by Connaught Laboratories, Inc. (Swiftwater, Pennsylvania), for use by certain travelers to and expatriates in Asia. Recommendations for vaccine use are forthcoming from the Advisory Committee on Immunization Practices.

^{*}Use of trade names and commercial sources is for identification only and does not imply endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Notices to Readers — Continued

Combined Issues of MMWR

A January 1, 1993, issue of *MMWR* will not be published. The next issue will be Volume 41, Numbers 52 and 53, dated January 8, 1993, and will include the figures and tables on notifiable diseases and deaths for the weeks ending December 26, 1992, and January 2, 1993.

Erratum: Vol. 41, No. SS-4

In the *CDC Surveillance Summaries* (no. SS-4) article "Surveillance in Evacuation Camps After the Eruption of Mt. Pinatubo, Philippines," Table 1 on page 11 contained errors. The table is printed below with corrections in italics.

TABLE 1. Causes of morbidity and mortality in evacuation camps — Philippines, June 16-September 7, 1991

Diseases	Consultations (N=74,962)	Deaths (N=349)	CFR*
Diarrhea	19,498 (26%)	101	0.5%
Measles	465 (1%)	107	23.0%
ARI†	18,973 (25%)	77	0.4%
Other	36,026 (48%)	64	0.2%

*CFR = case-fatality ratio

[†]ARI = acute respiratory infection



The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available on a paid subscription basis from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 783-3238.

The data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the succeeding Friday. Inquiries about the *MMWR* Series, including material to be considered for publication, should be directed to: Editor, *MMWR* Series, Mailstop C-08, Centers for Disease Control and Prevention, Atlanta, GA 30333; telephone (404) 332-4555.

Director, Centers for Disease Control and Prevention William L. Roper, M.D., M.P.H.	Editor, <i>MMWR</i> Series Richard A. Goodman, M.D., M.P.H.
Deputy Director, Centers for Disease Control and Prevention Walter R. Dowdle, Ph.D. Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Managing Editor, <i>MMWR</i> (weekly) Karen L. Foster, M.A. Writers-Editors, MMWR (weekly) David C. Johnson Barbara J. Reynolds, M.A. Caran R. Wilbanks
	Editorial Assistant, MMWR (weekly) Darlene D. Rumph

☆U.S. Government Printing Office: 1993-733-131/67051 Region IV

Penalty for Private Use \$300

Official Business

FIRST-CLASS MAIL POSTAGE & FEES PAID PHS/CDC Permit No. G-284